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Abstract:
Cytochrome P450 monooxygenases catalyze the metabolism of approximately 40-60% of widely used drugs with a A6986G
CYP3A5 polymorphism determining expresser (A6986, *1) and reduced- expresser (*3) variants with modified drug metabolism
activity. In this report, the allele frequency of CYP3A5 *1 and *3 (A6986 or G6986, respectively) was analyzed by the PCR-RFLP
techniqueinacohortof200PolishnewbornsfromtheWestPomeranianregion.Ofthestudiedgroup,1%(n=2/200)provedhomo-
zygousfortheCYP3A5*1allele,89%(n=178/200)forthe*3allele,and10%(n=20/200)wereheterozygousfor*1/*3.Similarfre-
quencies were found in other Caucasian European populations. This study provides basic genetic data related to the metabolism of
drugs, with a narrow therapeutic window in a Polish population.
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Introduction
The cytochrome P450 family is a group of enzymes
with primary monoxygenase activity, which is in-
volved in the metabolism of approximately 40–60% of
the drugs in everyday clinical use, oxidizing a range
of compounds, including steroids, fatty acids, immu-
nosuppressants and chemotherapeutic agents (e.g., cy-
closporine, trastuzumab and erlotinib). Cytochromes
are transmembrane proteins bound to the endoplasmic
reticulum and outer mitochondrial membrane. They
are abundantly expressed in virtually every human tis-
sue and organ, with the sole exception of striated mus-
cle fibers and erythrocytes. The highest enzymatic ac-
tivity was described for the liver and adrenal cortex.
The CYP3A subfamily (P450 3A) consists of the
3A5 enzyme and three other isoforms, namely CYP3A4,
CYP3A7 and CYP3A43, as well as two pseudogenes,
CYP3AP1 and CYP3AP2 [24]. Functionally, CYP3A5
is responsible for 6% to 99% of total CYP3A activity
in various populations, with negligible contributions
from CYP3A43 and CYP3A7 isoforms. An array of
genes is responsible for the coding of various P450 iso-
forms, with high sequence homology within the family
and the gene encoding for CYP3A5 located on the 7q22.1
chromosome [11, 12]. Sequence data were independently
published by two research groups [1, 8, 17, 20].
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individual differences in enzymatic activity, strongly
influencing pharmacokinetics and bioavailability of
an array of drugs with a narrow therapeutic window,
as well as the individual response to the drug therapy
[2, 5, 15]. The most frequent single nucleotide poly-
morphism (SNP) of functional importance in the
CYP3A5 gene is the Ato G transition in intron 3 at po-
sition 6986 (CYP3A5*3) [17]. This variant leads to al-
ternative splicing with impaired protein synthesis, re-
sulting in a decrease in metabolic activity. Conversely,
the presence of the wild-type, expresser-related A6986
allele (CYP3A5*1) leads to the phenotype of high
CYP3A5 catalytic activity. In CYP3A5 expressers,
dose requirements for certain immunosuppressants,
such as tacrolimus, tend to be higher, while clearance
of the anxiolytic midazolam is slower among indi-
viduals with a *3 genotype [5, 9]. It must be noted
that data from various pharmacogenetic studies are
often conflicting, especially in the case of midazolam.
Some studies do not confirm that CYPA5*1 allele car-
riers metabolize the drug better than individuals with
other variants [9]. The frequency of the CYP3A5*3
variant differs among populations and races, ranging
from 27–50% in the Afro-American population,
60–70% among Asians, and up to 85-95% in indi-
viduals of Caucasian ancestry, in which the expresser
variant is uncommon.
Distribution of the CYP3A5 alleles has not been re-
ported in the Polish population. It therefore remains uncon-
firmed if the allelic frequency falls within the assumed
range. Moreover, as the variant affects drug metabolism of
a range of drugs, including immunosuppressants (e.g., tac-
rolimus, cyclosporine, docetaxel, nifedipine), such exact
findings can be of clinical benefit.
The aim of this study was to analyze the distribution of
the CYP3A5 variants in a group of newborn Polish chil-
dren. Basic genetic data on the allele frequency in the ran-
domly selected sample are provided, bridging the gap in
the knowledge on CYP alleles in a population of Poles.
Material and Methods
Ethical issues
Local ethical committee approval was obtained for
the study protocol, sample collection, DNAextraction
and storage. Awritten formal consent for collection of
umbilical blood samples, DNAextraction, storage and
analysis was obtained from neonates’parents.
Samples and DNA isolation
The studied population consisted of 200 consecu-
tively born newborns delivered at the Neonatology
Department, Pomeranian Medical University, Szcze-
cin, Poland. Gender distribution in the group was as
follows: 106 female (53%) and 94 male (47%). Ge-
nomic DNAwas extracted from 100 µL of infants’um-
bilical cord blood with the QIAamp DNA Blood Mini
Kit (QIAGEN, Germany), and DNA yields were esti-
mated by measuring the absorbance at 260 nm (A￿￿￿).
PCR- RFLP for CYP3A5 variant alleles
Approximately 20 ng of genomic DNA was used in
a 10 µL PCR reaction. The PCR mixture contained:
the buffer (pH 8.3, 1.5 mM MgCl￿), 0.2 mM each of
the deoxynucleotide triphosphates, 0.5 U Taq polymerase
(MBI Fermentas, Lithuania) and 4 pmol each of the
forward and reverse primers designed by Schaik et al.
[23]. The forward primer sequence was 5’-CAT CAG
TTA GTA GAC AGA TGA, and the reverse primer
sequence was 5’-GGT CCA AAC AGG GAA GAA
ATA (TIB MOL BIOL, Poznañ, Poland). PCR reac-
tions were performed in a Mastercycler Gradient de-
vice (Eppendorf, Germany) with the following tem-
perature profiles: initial denaturation at 94°C for 5 min,
36 cycles of 20 s at 94°C, 40 s at 50°C and 40 s at
72°C, and a final extension step at 72°C for 7 min.
Amplification was followed by digestion of a 293-bp
product with the SspI restriction enzyme (MBI Fer-
mentas, Lithuania) for 18 h at 37°C. The PCR diges-
tion products were separated in 4% agarose gels,
stained with ethidium bromide and recorded with the
DS- 34 Polaroid Instant Camera (Polaroid, Germany)
under UV light (Transiluminator 4000, Stratagene). SspI
digestion yielded fragments of 168, 148, 125 and 20 bp
(heterozygote *1/*3), 148, 125 and 20 bp (homozygote
*1/*1), and 168 and 125 bp (homozygote *3/*3).
Results and Discussion
The frequency of all genotypes showed no deviation
from Hardy-Weinberg equilibrium (HWE). In the
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1% (n = 2) were homozygous for the *1 allele, 89%
(n = 178) for the *3 allele, and 10% (n = 20) were
*1/*3 heterozygotes. As was expected, among the
Caucasian population, the mutated *3 allele was nota-
bly more frequent (94%) when compared to the
wildtype *1 (6%). This is in accordance with previ-
ously published data, as reviewed in Table 1.
Highly similar frequencies were observed for Ger-
man, Finnish, Swedish and Greek populations [2, 7,
11, 14, 17, 22]. Interestingly, the allelic frequencies
described in our work are not significantly different
from the ones published for the Baltic Sea area. How-
ever, the distribution of the non-expresser *3 allele is
the lowest in the region [7, 14]. This confirms the
trend described of the notably increasing gradient of
CYP3A5*1 allele frequency from north to south of the
globe [17–19], with a smaller increase among Asians
compared to individuals of Caucasian ancestry [3, 5, 10].
It should be emphasized that Poland is inhabited by
a population with a high frequency of the non-
expresser *3 allele, as shown in our study. These
CYP3A5 genotypes have been associated with the
lower mean clearances of benzodiazepines and etopo-
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Country/(Population) Population (n) CYP 3A5 References
allele frequency
*1 *3
Poland/(Caucasians) Healthy newborn infants, (200) 0.060 0.940 Present study
USA/(Caucasians) Healthy adults, (54) 0.148 0.852 [17]
German/(Caucasians) Healthy adults, (428) 0.061 0.939 [7]
USA/(Afro-Americans) Healthy adults, (20) 0.450 0.475 [17] *
The Netherlands/ (Caucasians) Healthy adults, (500) 0.086 0,914 [23]
Finland/(Caucasians) Healthy adults, (449) 0.079 0.921 [14]
Korea/(Korean) Healthy adults, (29) 0.310 0.690 [6]
Japan/(Japanese) Healthy adults, (200) 0.233 0.767 [10]
Tanzania/(Afro-Americans) Healthy adults, (144) 0.510 0.190 [18] **
Sweden/(Caucasian) Healthy adults, (136) 0.070 0.930 [18]
East Asia/(Chinese) Healthy adults, (108) 0.245 0.755 [3]
South Asia/(Malay) Healthy adults, (98) 0.388 0.612 [3]
South Asia/(Indian) Healthy adults, (90) 0.406 0.594 [3]
Greece/(Greeks) Healthy adults, (283) 0.057 0.943 [2]
North America/(Caucasians) Healthy adults, (437) 0.093 0.907 [19]
USA/(Afro-Americans) Healthy adults, (38) 0.658 0.342 [19]
Korea/(Koreans) Healthy adults, (40) 0.225 0.775 [15]
Central America/(Afro-Americans) Healthy adults, (232) 0.237 0.763 [21]
North Spain/(Spaniard) Healthy adults, (204) 0.086 0.914 [21]
USA/(European-Americans) Healthy adults, (23) 0.130 0.870 [9]
USA/(Afro-Americans) Healthy adults, (34) 0.721 0.279 [9]
Finnish/(Caucasians) Healthy adults, (754) 0.070 0.930 [22]
USA/(Afro-Americans) Healthy adults, (25) 0.540 0.460 [11]
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related adverse reactions, such as peripheral neuropa-
thy [16].
Additionally, a strong association between the
CYP3A5*1 genotype and tacrolimus dose requirement
was observed. This is especially important because
the most effective immunosuppressive therapy is re-
quired for adequate protection against transplant re-
jection, in the case of chemotherapy in bone marrow
recipients and lymphoproliferative disease treatment
[6, 13]. This allele is infrequent in Poland and other
European populations [9]. The exact correlation be-
tween CYP3A5 genotypes and drug metabolism needs
to be further analyzed, and clear relationships be-
tween genetic variants and type of CYP expression
needs to be confirmed.
CYP3A5 allele frequency changes prove to be
largely race- and ancestry-dependent, with high simi-
larities described in countries from similar regions. In
American populations, the observed decrease might
be related to the inclusion of a population with a dif-
ferent ancestry into the genetic pool [19].
For this study, a random sample of newborns (all of
Caucasian origin) from the northwestern area of Po-
land was selected. This provided basic information on
the CYP3A5 allele frequency for future pharmacoge-
netic studies, as well as enabling analysis of possible
age-related effects on the prevalence of this variant.
Additionally, this studied neonatal population
might be considered an excellent genetic sample from
the largely immigrant population of Poles living in the
northwestern area of the country. Random enrollment
to the study with samples drawn from subsequent
children delivered at the obstetric ward allowed ex-
cluding the possibility of population bias and stratifi-
cation. This is possibly the only moment of life when
such sampling is possible, with no division due to so-
cial differences, as all childbearing women in Poland
are state insured with full and unlimited access to ob-
stetric and gynecologic care and follow-up. There-
fore, we would like to emphasize the value of this
data, which may serve as a background for compari-
son with other population samples and could be in-
cluded in case-control studies as a reference. A simi-
larly designed study for apolipoprotein E alleles was
performed by Becher et al. to provide the most ade-
quate population allelic frequencies [4].
With the development of therapeutic options and
wide access to drugs, the notion of tailored therapy
will undergo further development. Therapeutic drug
monitoring, currently expensive and rare in clinical
use, proves most valuable in cancer and antiviral ther-
apy. However, it might be partially replaced by ge-
netic marker data, assuming valid research data of
drug metabolism and concentrations in association
with gene variants are published. It is not only desir-
able, but also feasible for CYP3A polymorphisms, as
genotype data might allow the prediction of serum
concentrations of certain drugs. Based on this data, it
would be possible to adjust drug dose or select the
best therapeutic options for an individual.
In summary, it might be concluded that frequency
of the CYP3A1 allele is as low as 6%. Therefore, rapid
CYP3A5-dependent metabolism of immunosuppres-
sants such as tacrolimus is infrequent in our popula-
tion. Although this study was carried out in a popula-
tion from a single region, the distribution is similar to
the ones observed for other European populations [7,
18] and the CYP3A5 *1 and *3 frequencies in Poland
should not differ notably.
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